Reata Pharmaceuticals, Inc. Loss Submission Form
Company: Reata Pharmaceuticals, Inc.
Ticker: (NASDAQ) RETA
Deadline
Passed
Lead Plaintiff Deadline: December 14, 2020
Never Miss Another Deadline
Choose your preferred way to stay informed of new case launches and settlement deadlines.
Get Updates by Email
Subscribe for email notifications.
Allegations
(i) the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of FA in the U.S. without additional evidence; (ii) as a result, it was foreseeable that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.